Last edition
News about "Acute Myeloid Leukaemia"
Moleculin Reports Encouraging Interim Phase 2/3 Data for Annamycin in Relapsed or Refractory AML
Moleculin Biotech has reported encouraging preliminary blinded data from its pivotal Phase 2/3 MIRACLE trial, with Annamycin plus cytarabine achieving a 37 percent composite complete remission rate in relapsed or refractory acute myeloid leukaemia.
Acute Myeloid Leukaemia | 03/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members